Effects of Combined Formulation of Metformin, Pioglitazone and Aqueous Extract of Delonix Regia on Serum Levels of Gonadal Steroids (Testosterone and Progesterone) of Streptozotocin-Induced Diabetic Male and Female Wistar Albino Rats

The effects of Delonix regia extract (d200mg, d300mg, and d400mg), metformin (m8.3mg, m12.5mg and m16.5mg), pioglitazone (p0.5mg, p0.7mg and p0.9mg) and combined formulation of metformin and extract (m6.25,d150mg) on progesterone and testosterone levels in streptozotocin-induced diabetic Albino wistar rats was verified. Diabetic status of these rats was assessed by estimating fasting blood glucose levels. A total of 150 albino rats were used for the investigation and were grouped into twelve groups of twelve rats each as follows; Group I: normal control rats (NCR). Group II: Diabetic control rats (DCR). Group III: Diabetic rats treated with d200mg. Group IV: Diabetic rats treated with d300mg. Group V: Diabetic rats treated with d400mg. Group VI: Diabetic rats treated with m8.3mg. Group VII: Diabetic rats treated with m12.5mg. Group VIII: Diabetic rats treated with m16.5mg. Group IX: Diabetic rats treated with p0.5mg. Group X: Diabetic rats treated with p0.75mg. Group XI: Diabetic rats treated with p1.0mg. Group XII: Diabetic rats treated with m125d300mg each for male and female respectively, for a total of 56 days. After every two weeks interval of treatment for eight weeks three rats from each group were sacrificed and blood samples collected and analyzed for various parameters. The result obtained showed a reduction in the levels of testosterone and progesterone hormones in diabetic-induced wistar albino rats compared with normal control rats. However, these were reversed when treated with the drug/extract. Also, there was reduction in the blood glucose level of the diabetic rats treated with metformin (from 6.37±0.69 to 5.20±0.62mmol/l), pioglitazone (from 7.30±0.21mmol/l to 4.70±0.46), aqueous extract of Delonix regia (from 8.20±0.81mmol/l to 6.10±0.60) and combined formulation of metformin and extract (from 7.81±0.34 to 4.80±0.17), at p<0.05 confidence level when compared with diabetic control rats in the various weeks of treatment respectively.

The effects of Delonix regia extract (d200mg, d300mg, and d400mg), metformin (m8.3mg, m12.5mg and m16.5mg), pioglitazone (p0.5mg, p0.7mg and p0.9mg) and combined formulation of metformin and extract (m6.25,d150mg) on progesterone and testosterone levels in streptozotocin-induced diabetic Albino wistar rats was verified. Diabetic status of these rats was assessed by estimating fasting blood glucose levels. A total of 150 albino rats were used for the investigation and were grouped into twelve groups of twelve rats each as follows; Group I: normal control rats (NCR). Group II: Diabetic control rats (DCR). Group III: Diabetic rats treated with d200mg. Group IV: Diabetic rats treated with d300mg. Group V: Diabetic rats treated with d400mg. Group VI: Diabetic rats treated with m8.3mg. Group VII: Diabetic rats treated with m12.5mg. Group VIII: Diabetic rats treated with m16.5mg. Group IX: Diabetic rats treated with p0.5mg. Group X: Diabetic rats treated with p0.75mg. Group XI: Diabetic rats treated with p1.0mg. Group XII: Diabetic rats treated with m125d300mg each for male and female respectively, for a total of 56 days. After every two weeks interval of treatment for eight weeks three rats from each group were sacrificed and blood samples collected and analyzed for various parameters. The result obtained showed a reduction in the levels of testosterone and progesterone hormones in diabetic-induced wistar albino rats compared with normal control rats. However, these were reversed when treated with the drug/extract. Also, there was reduction in the blood glucose level of the diabetic rats treated with metformin (from 6.37±0.69 to 5.20±0.62mmol/l), pioglitazone (from 7.30±0.21mmol/l to 4.70±0.46), aqueous extract of Delonix regia (from 8.20±0.81mmol/l to 6.10±0.60) and combined formulation of metformin and extract (from 7.81±0.34 to 4.80±0.17), at p<0.05 confidence level when compared with diabetic control rats in the various weeks of treatment respectively.